Can a drug calm uncontrollable movements? new trial tests tetrabenazine
NCT ID NCT01543321
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 3 trial tested whether tetrabenazine (Xenazine) can reduce involuntary movements in people with tardive dyskinesia, a condition caused by long-term use of antipsychotic medications. Fifty-four adults with persistent symptoms were randomly assigned to receive either tetrabenazine or a placebo for 10 weeks. The study measured changes in movement severity using a standard rating scale.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Tetrabenazine (Xenazine)
What this could lead to
If successful, this could provide a proven treatment option to reduce involuntary movements in people with tardive dyskinesia, improving their quality of life.
What could go wrong
This is a small Phase 3 trial with only 54 participants, so results may not apply to everyone. Tetrabenazine can cause side effects like drowsiness or parkinsonism, and the benefit may be modest.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TARDIVE DYSKINESIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AP-HM Hopital de la Timone
Marseille, 13385, France
-
CH Aix en Provence
Aix-en-Provence, 13100, France
-
CH des Charpennes
Lyon, 69100, France
-
CHRU Lille
Lille, 59037, France
-
CHRU de Nimes
Nîmes, 30900, France
-
CHU Amiens
Amiens, Picardie, 80000, France
-
CHU Bordeaux
Bordeaux, 33076, France
-
CHU Caen
Caen, 14033, France
-
CHU Clermont-Ferrand
Clermont-Ferrand, 63003, France
-
CHU Limoges
Limoges, 87042, France
-
CHU Montpellier
Montpellier, 34295, France
-
CHU Nantes
Nantes, 44093, France
-
CHU Nice
Nice, 06002, France
-
CHU Poitiers
Poitiers, 86021, France
-
CHU Rouen
Rouen, 76031, France
-
CHU Saint Antoine
Paris, 75012, France
-
CHU Strasbourg
Strasbourg, 67091, France
-
CHU Toulouse
Toulouse, 31059, France
-
CHU de Rennes
Rennes, 35033, France